Skip to main content
Thursday, November 12, 2026Nov 12

Vanderbilt recruiting up to 1,000 for COVID-19 vaccine trial

Concept of SARS-CoV-2 or 2019-ncov coronavirus - stock photo coronavirus tile virus tile covid19 covid-19 tile / Getty Images
Concept of SARS-CoV-2 or 2019-ncov coronavirus - stock photo coronavirus tile virus tile covid19 covid-19 tile / Getty Images Concept of SARS-CoV-2 or 2019-ncov coronavirus - stock photo coronavirus tile virus tile covid19 covid-19 tile / Getty Images

NASHVILLE, Tenn. (AP) — Vanderbilt University Medical Center is looking for up to 1,000 volunteers to participate in the late-stage trial of an experimental COVID-19 vaccine.

The hospital says it will begin recruiting people at the end of the month. The vaccine is being developed by Moderna Inc. with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

The randomized, placebo-controlled phase 3 trial will be open to people 18 or older. They will receive two shots of either the vaccine or an inactive placebo and will be followed for two years.

The trial aims to determine how effective the vaccine is in protecting against COVID-19 and how long the protection lasts.

Officials say several U.S. centers are participating in the nationwide phase 3 trial, which will enroll 30,000 volunteers over the next two months.